Novo Nordisk shares plunge as oral semaglutide Alzheimer's trial fails to show clinical benefit

Core Viewpoint - Shares of Novo Nordisk experienced a significant decline following the announcement of disappointing results from a trial assessing the efficacy of its oral semaglutide in slowing Alzheimer's disease progression [1] Group 1 - The trial aimed to evaluate the potential of oral semaglutide as a treatment for Alzheimer's disease [1] - The announcement of the trial results led to a sharp drop in Novo Nordisk's stock price [1]